ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1383

T-Cell Subset Analysis in IgG4-Related Disease and Lymphocyte-Variant Hypereosinophilic Syndrome

Mollie Carruthers1, Bakul Dalal2, Sujin Park3, Graham Slack2, Andre Mattman4 and Luke Chen5, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2Pathology, University of British Columbia, Vancouver, BC, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Medical Biochemistry, University of British Columbia, Vancouver, BC, Canada, 5Hematology, University of British Columbia, Vancouver, BC, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: IgG4 Related Disease and biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

IgG4-related disease (IgG4-RD) and lymphocyte-variant hypereosinophilic syndrome (L-HES) share elevated peripheral eosinophilia and IgE levels as well as common clinical features including atopy, cutaneous lesions and lymphadenopathy. Distinguishing between these two diseases is a diagnostic challenge.  L-HES is driven by an aberrant population of T lymphocytes characterized by an abnormal immunophenotype, clonal T-cell receptor rearrangements, or both.  Determining whether there is overlap in the immunphenotype of T-cells in IgG4-RD with L-HES will be helpful in the diagnosing and understanding the pathophysiology of these conditions.

Methods:

IgG4-RD patients were biopsy proven according to consensus guidelines and HES patients fit WHO criteria for HES including persistent blood eosinophilia >1,500/mm3 at a single Canadian academic center. There were 9 patients with L-HES and 11[p1]  patients with IgG4-related disease. Peripheral blood T-cell immunophenotyping was performed by multicolor flow cytometry using an antibody panel consisting of CD2, 3, 4, 7, 8, 45 and 56. Polymerase chain reaction was used to analyze T-cell receptor clonality.

Results:

There were three IgG4-related disease patients with elevated CD4+/7- T-cell subsets median 14.5% (range 11-16.5; cut-off>10) and 6 additional IgG4-RD patients had normal subsets. Two IgG4-related disease patients had elevated NK cells. None of the IgG4-RD patients had a clonal T-cell receptor rearrangement by PCR.  All nine L-HES patients had an abnormal phenotype, including increased CD4+/3- (n=4), CD4+/3-/8- (n=3), CD4+/7- (n=1) and increased NK cells (n=1). There were 5 HES patients, out of 8 total measured, with clonal T-cell receptor rearrangements by PCR, including the patient with an elevated CD4+/7- population.[p2]

Conclusion:

Five of eleven patients with IgG4-RD had immunophenotypic abnormalities of the T-lymphocytes which overlap with the immunophenotypic abnormalities seen in L-HES.  However, none of the IgG4-RD patients had a clonal T-cell rearrangement by PCR, indicating that the expanded CD4+/7- and NK populations seen in this disease are likely a nonspecific finding also seen in other inflammatory/autoimmune disorders.


Disclosure: M. Carruthers, None; B. Dalal, None; S. Park, None; G. Slack, None; A. Mattman, None; L. Chen, None.

To cite this abstract in AMA style:

Carruthers M, Dalal B, Park S, Slack G, Mattman A, Chen L. T-Cell Subset Analysis in IgG4-Related Disease and Lymphocyte-Variant Hypereosinophilic Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/t-cell-subset-analysis-in-igg4-related-disease-and-lymphocyte-variant-hypereosinophilic-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/t-cell-subset-analysis-in-igg4-related-disease-and-lymphocyte-variant-hypereosinophilic-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology